Seemal R. Desai

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Abstract There is an unmet need for repigmentation therapies for patients with nonsegmental vitiligo (NSV) who are candidates for systemic therapy. Here, 52-week primary results are reported from two parallel phase 3, randomized, double-blind, placebo-controlled trials of once-da...